Business
Novartis to acquire UK-based Myricx Bio for $1.5 billion
RTÉSwiss drugmaker Novartis said today it had agreed to pay up to $1.5 billion for UK-based biotechnology firm Myricx Bio in a deal expected to close in the second half of 2026.
RTÉSwiss drugmaker Novartis said today it had agreed to pay up to $1.5 billion for UK-based biotechnology firm Myricx Bio in a deal expected to close in the second half of 2026.